The Journal of Practical Medicine >
Clinical efficacy of Niaoduqing Granule combined with Febusta in treatment of hyperuricemia with renal damage
Received date: 2023-10-07
Online published: 2024-05-21
Objective To investigate the clinical efficacy of Niaoduqing Granule combined with Febusta in the treatment of renal damage in patients with hyperuricemia （HUA）. Methods Eighty-two HUA patients with renal damage in our hospital from March 2020 to March 2022 were divided into observation group （n = 41） and control group （n = 41）. The control group was treated with Febusta， while observation group with Niaoduqing granule and Febusta. Two groups were treated for 12 weeks. Blood uric acid， renal function， Cys C and β2-MG level change and adverse reactions in the two groups were compared. Results The total effective rate in the observation group was higher than in the control group （P < 0.05）. After treatment， the level of serum uric acid， BUN， Scr， 24h Upro， Cys C and β2-MG decreased in the two groups （P < 0.05）， with more significant results in the observation group （P < 0.05）. No obvious adverse reactions were observed in the two groups. Conclusion Niaoduqing Granule combined with Febusta has good effect in treating HUA patients with renal impairment. It reduces the level of blood uric acid， Cys C and β2-MG， which protect the renal function of patients，
Key words： Niaoduqing Granule; Febusta tablet; hyperuricemia; renal damage
Juan LI , Lin. YANG . Clinical efficacy of Niaoduqing Granule combined with Febusta in treatment of hyperuricemia with renal damage[J]. The Journal of Practical Medicine, 2024 , 40(10) : 1418 -1422 . DOI: 10.3969/j.issn.1006-5725.2024.10.015
| 1 | YANAI H， ADACHI H， HAKOSHIMA M， et al. Molecular Biological and Clinical Understanding of the Pathophysiology and Treatments of Hyperuricemia and Its Association with Metabolic Syndrome， Cardiovascular Diseases and Chronic Kidney Disease［J］. Int J Mol Sci， 2021， 22（17）：9221. doi:10.3390/ijms22179221 |
| 2 | ZHANG M， CUI R， ZHOU Y， et al. Accumulation of Renal Fibrosis in Hyperuricemia Rats Is Attributed to the Recruitment of Mast Cells， Activation of the TGF-β1/Smad2/3 Pathway， and Aggravation of Oxidative Stress［J］. Int J Mol Sci， 2023， 24（13）：10839. doi:10.3390/ijms241310839 |
| 3 | WANG J， CHEN Y， ZHONG H， et al. The gut microbiota as a target to control hyperuricemia pathogenesis： Potential mechanisms and therapeutic strategies［J］. Crit Rev Food Sci Nutr， 2022，62（14）：3979-3989. doi:10.1080/10408398.2021.1874287 |
| 4 | SU H Y， YANG C， LIANG D， et al. Research Advances in the Mechanisms of Hyperuricemia-Induced Renal Injury［J］. Biomed Res Int， 2020， 2020：5817348. doi:10.1155/2020/5817348 |
| 5 | LI H， LIU X， LEE M H， et al. Vitamin C alleviates hyperuricemia nephropathy by reducing inflammation and fibrosis［J］. J Food Sci， 2021， 86（7）：3265-3276. doi:10.1111/1750-3841.15803 |
| 6 | YANG H T， XIU W J， LIU J K， et al. Gut Microbiota Characterization in Patients with Asymptomatic Hyperuricemia： probiotics increased［J］. Bioengineered，2021，12（1）：7263-7275. doi:10.1080/21655979.2021.1976897 |
| 7 | LI F， WANG M， WANG J， et al. Alterations to the gut microbiota and their correlation with inflammatory factors in chronic kidney disease［J］. Front Cell Infect Microbiol， 2019，9：206. doi:10.3389/fcimb.2019.00206 |
| 8 | CRISTOBAL-GARCIA M， GARCIA-ARROYO F E， TAPIA E， et al. Renal oxi dative stress induced by long-term hyperuricemia alters mitochon drial function and maintains systemic hypertension［J］. Oxid Med Cell Longev， 2015，2015：535686. doi:10.1155/2015/535686 |
| 9 | 高尿酸血症相关疾病诊疗多学科共识专家组. 中国高尿酸血症相关疾病诊疗多学科专家共识［J］. 中华内科杂志， 2017，56（3）：235-248. doi:10.3760/cma.j.issn.0578-1426.2017.03.021 |
| 10 | PAN J， SHI M， MA L， et al. Mechanistic insights of soluble uric acid-related kidney disease［J］. Curr Med Chem， 2020， 27（30）： 5056-5066. doi:10.2174/0929867326666181211094421 |
| 11 | XIONG C， DENG J， WANG X， et al. Pharmacologic targeting of BET proteins attenuates hyperuricemic nephropathy in rats［J］. Front Pharm， 2021， 12： 636154. doi:10.3389/fphar.2021.636154 |
| 12 | ZENNARO C， TONON F， ZARATTINI P， et al. The renal phenotype of allopurinol-treated HPRT-deficient mouse［J］. PLoS One， 2017， 12（3）： e0173512. doi:10.1371/journal.pone.0173512 |
| 13 | ZHANG D， HUANG Q F， LI Y， et al. Incident hyperuricemia in relation to antihypertensive therapy with the irbesartan/hydrochlorothiazide combination［J］. Blood Press Monit， 2021，26（6）：413-418. doi:10.1097/mbp.0000000000000554 |
| 14 | SUN Z R， LIU H R， HU D， et al. Ellagic Acid Exerts Beneficial Effects on Hyperuricemia by Inhibiting Xanthine Oxidase and NLRP3 Inflammasome Activation［J］. J Agric Food Chem， 2021，69（43）：12741-12752. doi:10.1021/acs.jafc.1c05239 |
| 15 | CHEN F， YUAN L， XU T， et al. Association of Hyperuricemia with 10-Year Atherosclerotic Cardiovascular Disease Risk among Chinese Adults and Elders［J］. Int J Environ Res Public Health， 2022， 19： 6713. doi:10.3390/ijerph19116713 |
| 16 | LONG T， LIU L. Research Progress on the Relationship between Dietary Patterns and Hyperuricemia ［J］. Appl Bionics Biomech， 2022， 2022： 1263-1270. doi:10.1155/2022/5658423 |
| 18 | 伍成凯， 廖生武， 方浩庭， 等. 广州市成年人高尿酸血症患病情况调查及其影响因素分析［J］. 实用医学杂志， 2021， 37（23）： 3072-3076. doi:10.3969/j.issn.1006-5725.2021.23.022 |
| 19 | LIU P， MA G， WANG Y， et al. Therapeutic effects of traditional Chinese medicine on gouty nephropathy： Based on NF-κB signaling pathways［J］. Biomed Pharmacother， 2023， 158：114199. doi:10.1016/j.biopha.2022.114199 |
| 20 | MIRONOVA O I. Hyperuricemia and kidney damage in patients with cardiovascular disease： A review［J］. Ter Arkh， 2023， 4（12）：1426-1430. doi:10.26442/00403660.2022.12.201999 |
| 21 | 陈如萍， 刘蕊， 孙遨， 等. 基于社区老年健康体检人群的慢性肾脏病流行病学调查［J］. 实用医学杂志， 2021， 37（13）： 1755-1760. |
| 22 | YU C S H， FANG H H， YU Z P， et al. Overview of advances in Chinese medicine for the treatment of gouty nephropathy［J］， J Emerg Tradit Chin Med， 2020， 29： 4. |
| 23 | 郭文燕，李燕林. 尿毒康合剂联合非布司他治疗湿热瘀阻型痛风性肾病疗效评价［J］. 广州中医药大学学报， 2021，38（7）：1335-1340. |
/
| 〈 |
|
〉 |